RxDoctor Payments Data

Euclid St Hill, MD

Nephrology · North Sioux City, SDNPI 1740703990

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Boehringer Ingelheim at 27.9% of the total.

$815in general payments, 2019–2025

Across 27 payments — averaging $30.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$227
  • Bayer$166
  • Fresenius USA Marketing, Inc.$67
  • Aurinia Pharma U.S., Inc.$62
  • Nestle Healthcare Nutrition Inc.$53
  • Novartis$50
  • plus $190 from 7 others

What the payments were for

  • Food & beverage$815100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$815 in reported general payments places this provider in the 80th percentile of 26 nephrology providers in South Dakota.

See all nephrology providers in South Dakota

Medicare billing

Part B allowed, 2024
$591,700
Medicare patients
1,005
Services billed
7,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide16$41,984
FarxigaDapagliflozin Propanediol18$10,953
Sevelamer Carbonate46$3,807
LokelmaSodium Zirconium Cyclosilicate11$2,865
Cinacalcet Hcl20$897
Potassium Chloride46$648
Bumetanide24$616
Amlodipine Besylate73$409
Hydralazine Hcl30$407
Allopurinol61$283
Furosemide74$247
Calcitriol31$223
Losartan Potassium35$219
Ropinirole Hcl12$211
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$67$41,98416 claims
AstraZenecaFarxiga, Lokelma$18$13,81829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 26 nephrology providers in South Dakota.

Other nephrology in North Sioux City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →